TerminatedPhase 2NCT01186406

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Duke University
Principal Investigator
Annick Desjardins, MD, FRCPC, M.D
Duke University
Intervention
Gliadel(drug)
Enrollment
41 enrolled
Eligibility
18 years · All sexes
Timeline
20112014

Study locations (1)

Collaborators

Genentech, Inc. · Eisai Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01186406 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma

← Back to all trials